Li et al., 2012 - Google Patents
Anti–tumor necrosis factor–α monoclonal antibody alleviates parenteral nutrition–associated liver disease in miceLi et al., 2012
- Document ID
- 6027140674253666715
- Author
- Li J
- Gong Y
- Wu J
- Wu W
- Cai W
- Publication year
- Publication venue
- Journal of Parenteral and Enteral Nutrition
External Links
Snippet
Background: The authors aimed to investigate the role of anti–tumor necrosis factor (TNF)–α monoclonal antibody treatment in a mouse model of parenteral nutrition–associated liver disease (PNALD). Methods: C57BL/6J male mice (aged 6–8 weeks) were randomly …
- 206010074151 Parenteral nutrition associated liver disease 0 title abstract description 26
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Anti–tumor necrosis factor–α monoclonal antibody alleviates parenteral nutrition–associated liver disease in mice | |
| Wu et al. | Interleukin 22 in liver injury, inflammation and cancer | |
| Singh et al. | Treatment options for alcoholic and non-alcoholic fatty liver disease: A review | |
| Nigam et al. | The systems biology of uric acid transporters: the role of remote sensing and signaling | |
| Marks et al. | Innate immunity in inflammatory bowel disease: a disease hypothesis | |
| Vachliotis et al. | The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease | |
| Yuan et al. | Fish oil alleviated high-fat diet–induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study | |
| Moseley | Sepsis and cholestasis | |
| Aghemo et al. | Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C | |
| Mundt et al. | Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake | |
| Kamari et al. | Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice | |
| Inaba et al. | Growth arrest and DNA damage‐inducible 34 regulates liver regeneration in hepatic steatosis in mice | |
| Harada et al. | Interferon γ accelerates NF-κB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction | |
| Harris et al. | Elevation of liver function tests in severe anorexianervosa | |
| Hupa-Breier et al. | Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH | |
| Zheng et al. | Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways | |
| Rivera et al. | Endotoxemia and hepatic injury in a rodent model of hindlimb unloading | |
| Wong et al. | Genetic polymorphisms of adiponectin and tumor necrosis factor‐alpha and nonalcoholic fatty liver disease in Chinese people | |
| Ren et al. | Endoplasmic reticulum stress-activated glycogen synthase kinase 3β aggravates liver inflammation and hepatotoxicity in mice with acute liver failure | |
| Liu et al. | Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats | |
| Shasthry et al. | New treatment options for alcoholic hepatitis | |
| Samami et al. | Inosine, gut microbiota, and cancer immunometabolism | |
| Tseng et al. | Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts | |
| Roth et al. | Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure | |
| Ibfelt et al. | The Acute Effects of Low‐Dose TNF‐α on Glucose Metabolism and β‐Cell Function in Humans |